CURC

About CURC

This author has not yet filled in any details.
So far CURC has created 172 blog entries.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Karim Fizazi, M.D., Neal Shore, M.D., Teuvo L. Tammela, M.D., Ph.D., Albertas Ulys, M.D., Egils Vjaters, M.D., Sergey Polyakov, M.D., Mindaugas Jievaltas, M.D., Murilo Luz, M.D., Boris Alekseev, M.D., Iris Kuss, M.D., Christian Kappeler, Ph.D., Amir Snapir, M.D., Ph.D., Toni Sarapohja, M.Sc., and Matthew R. Smith, M.D., Ph.D. for the ARAMIS Investigators* Background- Darolutamide is [...]

By | February 18th, 2019|

Managing Nonmetastatic Castration-resistant Prostate Cancer

Joaquin Mateo, Karim Fizazi, Silke Gillessen, Axel Heidenreich, Raquel Perez-Lopez, Wim J.G. Oyen, Neal Shore, Matthew Smith, Christopher Sweeney, Bertrand Tombal, Scott A. Tomlins, Johann S. de Bono. Correspondence information about the author Johann S. de Bono Associate Editor: Giacomo Novara Context Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and [...]

By | February 12th, 2019|

A New Sustained-Release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer

Neal D.Shore, MD, SílviaGuerrero, PhD, Rosa MaSanahuja, MS, GemmaGambús, MD, PhD, AntonioParente, Ph Purpose This clinical trial investigated the effectiveness, pharmacokinetic properties, and safety profile of leuprolide acetate 22.5-mg depot, a new 3-month leuprolide depot formulation, as androgen deprivation therapy for patients with prostate cancer. click here to read more...

By | February 12th, 2019|

A New Sustained-Release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer

Neal D. Shore, MD1; Sílvia Guerrero, PhD2; Rosa Ma Sanahuja, MS2;Gemma Gambús, MD, PhD2; and Antonio Parente, PhD2 Purpose: This clinical trial investigated the effectiveness, pharmacokinetic properties, and safety profile of leuprolide acetate 22.5-mg depot, a new 3-month leuprolide depot formulation, as androgen deprivation therapy for patients with prostate cancer. Click here to read more

By | February 1st, 2019|

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) is a fully human IgG1 monoclonal antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE), which is designed to specifically bind PSMA‐positive cells, internalize, and then release its cytotoxic payload into the [...]

By | January 28th, 2019|

Bone Health in Prostate Cancer, A Conversation with Neal Shore and Oliver Sartor

Neal Shore and Oliver Sartor have a conversation on bone-targeted agent therapies in prostate cancer, specifically focusing on the ALSYMPCA phase three trial; the design, findings, the addition of radium 223 and what this trial has led to today. They review a few other current ongoing trials including the PEACE III single arm trial and [...]

By | January 28th, 2019|

Managing the Adverse Effects of Drug Treatments for Advanced Prostate Cancer

Ask The Experts: Neal D. Shore, MD Practice Community: Myrtle Beach, South Carolina Hospital and Institutional Affiliations: Director, CPI, Carolina Urologic Research Center, Myrtle Beach, South Carolina, and President of the Large Urology Group Practice Association Number of Patients Seen in a Week: 150 Practice Niche: Urologic Oncology click here to read entire Q&A

By | November 8th, 2018|

LUGPA president details decade of successes with eye on future

Chicago—A decade since its founding, LUGPA is looking to the future with ambitious goals aimed at sustaining and strengthening the practice of independent urology. That was the message of LUGPA President Neal D. Shore, MD, at the association’s 10thanniversary meeting in Chicago. Dr. Shore detailed 10 years of successes that span LUGPA’s initiatives in advocacy, [...]

By | November 5th, 2018|

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

E. David Crawford, Paul F. Schellhammer, David G. McLeod, Judd W. Moul‡, Celestia S. Higano, Neal Shore, Louis Denis, Peter Iversen, Mario A. Eisenberger, Fernand Labrie click here to read entire article

By | October 26th, 2018|